Anti-cancer activity of plant-produced HPV16 E7 vaccine

Silvia Massa, Rosella Franconi, Rossella Brandi, Antonio Muller, Vadim Mett, Vidadi Yusibov, Aldo Venuti

Research output: Contribution to journalArticlepeer-review


The E7 oncoprotein from Human Papilloma Virus (HPV) is an attractive candidate for anti-cancer vaccine development. In this study, we engineered HPV16 E7 coding sequence (wild type or mutagenized sequence, E7GGG) as fusions to β-1,3-1,4-glucanase (LicKM) of Clostridium thermocellum and produced in Nicotiana benthamiana plants using a transient expression system. Target antigens were purified and evaluated in mice for their potential as prophylactic and therapeutic vaccine candidates. Both fusion proteins induced E7-specific IgG and cytotoxic T-cell responses and protected mice against challenge with E7-expressing tumor cells. Furthermore, when administered after challenge, these plant-produced antigens prevented tumor development.

Original languageEnglish
Pages (from-to)3018-3021
Number of pages4
Issue number16 SPEC. ISS.
Publication statusPublished - Apr 20 2007


  • Cancer vaccine
  • Human papilloma virus
  • Plant-produced vaccine

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)


Dive into the research topics of 'Anti-cancer activity of plant-produced HPV16 E7 vaccine'. Together they form a unique fingerprint.

Cite this